{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T04:10:25Z","timestamp":1744517425484,"version":"3.40.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,12]]},"DOI":"10.7759\/cureus.82141","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T21:15:26Z","timestamp":1744492526000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Characteristics, Prognostic Factors, and Thrombotic and Bleeding Outcomes in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Single-Center Cohort Study in Thailand"],"prefix":"10.7759","author":[{"given":"Suprang","family":"Suttantapidok","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weerapat","family":"Owattanapanich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber DA","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al.. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016, 127:2391-405. 10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic\u00a0neoplasms","volume":"36","author":"Khoury JD","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al.. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic\u00a0neoplasms. Leukemia. 2022, 36:1703-19. 10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders","volume":"355","author":"Campbell PJ","year":"2006","unstructured":"Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006, 355:2452-66. 10.1056\/NEJMra063728","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott LM","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, et al.. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007, 356:459-68. 10.1056\/NEJMoa065202","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti F","year":"2011","unstructured":"Passamonti F, Elena C, Schnittger S, et al.. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011, 117:2813-6. 10.1182\/blood-2010-11-316810","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman Y","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, et al.. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006, 3:e270. 10.1371\/journal.pmed.0030270","journal-title":"PLoS Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-486050","article-title":"Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms","volume":"121","author":"Rumi E","year":"2013","unstructured":"Rumi E, Pietra D, Guglielmelli P, et al.. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood. 2013, 121:4388-95. 10.1182\/blood-2013-02-486050","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui T","year":"2013","unstructured":"Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013, 122:2176-84. 10.1182\/blood-2013-03-460154","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.72","article-title":"Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders","volume":"22","author":"Cervantes F","year":"2008","unstructured":"Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders. Leukemia. 2008, 22:905-14. 10.1038\/leu.2008.72","journal-title":"Leukemia"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-013-0176-z","article-title":"Are MPNs vascular diseases?","volume":"8","author":"Finazzi G","year":"2013","unstructured":"Finazzi G, De Stefano V, Barbui T. Are MPNs vascular diseases?. Curr Hematol Malig Rep. 2013, 8:307-16. 10.1007\/s11899-013-0176-z","journal-title":"Curr Hematol Malig Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23135","article-title":"Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management","volume":"87","author":"Tefferi A","year":"2012","unstructured":"Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012, 87:285-93. 10.1002\/ajh.23135","journal-title":"Am J Hematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study","volume":"30","author":"Hultcrantz M","year":"2012","unstructured":"Hultcrantz M, Kristinsson SY, Andersson TM, et al.. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012, 30:2995-3001. 10.1200\/JCO.2012.42.1925","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti F","year":"2010","unstructured":"Passamonti F, Rumi E, Pietra D, et al.. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010, 24:1574-9. 10.1038\/leu.2010.148","journal-title":"Leukemia"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000352088","article-title":"Association of oesophageal varices and splanchnic vein thromboses in patients with JAK2-positive myeloproliferative neoplasms: presentation of two cases and data from a retrospective analysis","volume":"6","author":"Link CS","year":"2013","unstructured":"Link CS, Platzbecker U, Kroschinsky F, et al.. Association of oesophageal varices and splanchnic vein thromboses in patients with JAK2-positive myeloproliferative neoplasms: presentation of two cases and data from a retrospective analysis. Case Rep Oncol. 2013, 6:311-5. 10.1159\/000352088","journal-title":"Case Rep Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell PJ","year":"2012","unstructured":"Campbell PJ, MacLean C, Beer PA, et al.. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood. 2012, 120:1409-11. 10.1182\/blood-2012-04-424911","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1331153","article-title":"Thrombotic and bleeding complications in classical myeloproliferative neoplasms","volume":"39","author":"McMahon B","year":"2013","unstructured":"McMahon B, Stein BL. Thrombotic and bleeding complications in classical myeloproliferative neoplasms. Semin Thromb Hemost. 2013, 39:101-11. 10.1055\/s-0032-1331153","journal-title":"Semin Thromb Hemost"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.314","article-title":"Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera","volume":"26","author":"Reikvam H","year":"2012","unstructured":"Reikvam H, Tiu RV. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia. 2012, 26:563-71. 10.1038\/leu.2011.314","journal-title":"Leukemia"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.02.023","article-title":"Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden","volume":"135","author":"Lim Y","year":"2015","unstructured":"Lim Y, Lee JO, Kim SH, et al.. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. Thromb Res. 2015, 135:846-51. 10.1016\/j.thromres.2015.02.023","journal-title":"Thromb Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00046-1","article-title":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations","volume":"9","author":"Marchetti M","year":"2022","unstructured":"Marchetti M, Vannucchi AM, Griesshammer M, et al.. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022, 9:e301-11. 10.1016\/S2352-3026(22)00046-1","journal-title":"Lancet Haematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-014-1567-1","article-title":"JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan","volume":"99","author":"Edahiro Y","year":"2014","unstructured":"Edahiro Y, Morishita S, Takahashi K, et al.. JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. Int J Hematol. 2014, 99:625-34. 10.1007\/s12185-014-1567-1","journal-title":"Int J Hematol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2886","article-title":"Thrombosis among 1537 patients with JAK2(V617F)-mutated myeloproliferative neoplasms: risk factors and development of a predictive model","volume":"9","author":"Zhang Y","year":"2020","unstructured":"Zhang Y, Zhou Y, Wang Y, et al.. Thrombosis among 1537 patients with JAK2(V617F)-mutated myeloproliferative neoplasms: risk factors and development of a predictive model. Cancer Med. 2020, 9:2096-105. 10.1002\/cam4.2886","journal-title":"Cancer Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-531665","article-title":"Causal role for JAK2 V617F in thrombosis","volume":"122","author":"Fleischman AG","year":"2013","unstructured":"Fleischman AG, Tyner JW. Causal role for JAK2 V617F in thrombosis. Blood. 2013, 122:3705-6. 10.1182\/blood-2013-10-531665","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10169","article-title":"Calreticulin mutations in myeloproliferative neoplasms","volume":"5","author":"Lavi N","year":"2014","unstructured":"Lavi N. Calreticulin mutations in myeloproliferative neoplasms. Rambam Maimonides Med J. 2014, 5:e0035. 10.5041\/RMMJ.10169","journal-title":"Rambam Maimonides Med J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19177","article-title":"Impact of non-driver gene mutations on thrombo-haemorrhagic events in ET patients","volume":"204","author":"Furuya C","year":"2024","unstructured":"Furuya C, Morishita S, Hashimoto Y, et al.. Impact of non-driver gene mutations on thrombo-haemorrhagic events in ET patients. Br J Haematol. 2024, 204:221-8. 10.1111\/bjh.19177","journal-title":"Br J Haematol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25303","article-title":"Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management","volume":"94","author":"Tefferi A","year":"2019","unstructured":"Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019, 94:133-43. 10.1002\/ajh.25303","journal-title":"Am J Hematol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui T","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, et al.. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012, 120:5128-33; quiz 5252. 10.1182\/blood-2012-07-444067","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes F","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, et al.. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009, 113:2895-901. 10.1182\/blood-2008-07-170449","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti F","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, et al.. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010, 115:1703-8. 10.1182\/blood-2009-09-245837","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21574","article-title":"Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis\u2014prognostic relevance is independent of IPSS or karyotype","volume":"85","author":"Tefferi A","year":"2010","unstructured":"Tefferi A, Siragusa S, Hussein K, et al.. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis\u2014prognostic relevance is independent of IPSS or karyotype. Am J Hematol. 2010, 85:14-7. 10.1002\/ajh.21574","journal-title":"Am J Hematol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-240135","article-title":"International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis","volume":"115","author":"Hussein K","year":"2010","unstructured":"Hussein K, Pardanani AD, Van Dyke DL, Hanson CA, Tefferi A. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood. 2010, 115:496-9. 10.1182\/blood-2009-08-240135","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"Rungjirajittranon T","year":"2019","unstructured":"Rungjirajittranon T, Owattanapanich W, Ungprasert P, Siritanaratkul N, Ruchutrakool T. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer. 2019, 19:184. 10.1186\/s12885-019-5387-9","journal-title":"BMC Cancer"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi A","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, et al.. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013, 27:1874-81. 10.1038\/leu.2013.163","journal-title":"Leukemia"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15048","article-title":"Definition of major bleeding: prognostic classification","volume":"18","author":"Franco L","year":"2020","unstructured":"Franco L, Becattini C, Beyer-Westendorf J, et al.. Definition of major bleeding: prognostic classification. J Thromb Haemost. 2020, 18:2852-60. 10.1111\/jth.15048","journal-title":"J Thromb Haemost"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S374636","article-title":"Clinical characteristics and prognostic risks of Philadelphia-negative myeloproliferative neoplasms at Cipto Mangunkusumo General Hospital","volume":"13","author":"Sukrisman L","year":"2022","unstructured":"Sukrisman L. Clinical characteristics and prognostic risks of Philadelphia-negative myeloproliferative neoplasms at Cipto Mangunkusumo General Hospital. J Blood Med. 2022, 13:495-503. 10.2147\/JBM.S374636","journal-title":"J Blood Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.11.005","article-title":"Epidemiology of the Philadelphia chromosome-negative classical myeloproliferative neoplasms","volume":"35","author":"Shallis RM","year":"2021","unstructured":"Shallis RM, Zeidan AM, Wang R, Podoltsev NA. Epidemiology of the Philadelphia chromosome-negative classical myeloproliferative neoplasms. Hematol Oncol Clin North Am. 2021, 35:177-89. 10.1016\/j.hoc.2020.11.005","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-638593","article-title":"White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study","volume":"126","author":"Barbui T","year":"2015","unstructured":"Barbui T, Masciulli A, Marfisi MR, Tognoni G, Finazzi G, Rambaldi A, Vannucchi A. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood. 2015, 126:560-1. 10.1182\/blood-2015-04-638593","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10634","article-title":"Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status","volume":"92","author":"Finazzi G","year":"2007","unstructured":"Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica. 2007, 92:135-6. 10.3324\/haematol.10634","journal-title":"Haematologica"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-206797","article-title":"Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?","volume":"114","author":"Barbui T","year":"2009","unstructured":"Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?. Blood. 2009, 114:759-63. 10.1182\/blood-2009-02-206797","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000936","article-title":"Application of IPSET-thrombosis in 1366 patients prospectively followed from the Spanish Registry of Essential Thrombocythemia","volume":"7","author":"Alvarez-Larr\u00e1n A","year":"2023","unstructured":"Alvarez-Larr\u00e1n A, Cuevas B, Velez P, et al.. Application of IPSET-thrombosis in 1366 patients prospectively followed from the Spanish Registry of Essential Thrombocythemia. Hemasphere. 2023, 7:e936. 10.1097\/HS9.0000000000000936","journal-title":"Hemasphere"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/355108-clinical-characteristics-prognostic-factors-and-thrombotic-and-bleeding-outcomes-in-philadelphia-chromosome-negative-myeloproliferative-neoplasms-a-single-center-cohort-study-in-thailand","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T21:15:27Z","timestamp":1744492527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/355108-clinical-characteristics-prognostic-factors-and-thrombotic-and-bleeding-outcomes-in-philadelphia-chromosome-negative-myeloproliferative-neoplasms-a-single-center-cohort-study-in-thailand"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.82141","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,12]]}}}